Solventum Corporation (SOLV)
$
72.87
+0.71 (0.97%)
Key metrics
Financial statements
Free cash flow per share
0.8443
Market cap
12.6 Billion
Price to sales ratio
1.5063
Debt to equity
2.1440
Current ratio
1.2244
Income quality
1.5421
Average inventory
914 Million
ROE
0.1164
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Solventum Corporation, a healthcare company incorporated in 2023 and based in Saint Paul, Minnesota, is focused on developing, manufacturing, and commercializing a diverse range of solutions to meet critical customer and patient needs. The company operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment offers an array of products, including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. Meanwhile, the Dental Solutions segment provides an extensive suite of dental and orthodontic products such as brackets, aligners, restorative cements, and bonding agents. Health Information Systems is dedicated to delivering software solutions like computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. In addition, the Purification and Filtration segment features advanced purification and filtration technologies encompassing filters, purifiers, cartridges, and membranes. The company's operating expenses amount to $3,557,000,000.00 encompassing various operational costs incurred. With reported revenue of $8,254,000,000.00 the company reflects a strong market presence. Moreover, the operating income ratio stands at 0.13 indicating the company's operational profitability margin, while the weighted average number of shares outstanding is 173,200,000.00 highlighting the company's shareholder base. The company's stock is identified with the symbol 'SOLV' in the market. Investors will find the stock reasonably priced at $73.72 appealing to a broad range of market participants. With an average trading volume of 1,091,828.00 the stock indicates moderate liquidity, which can facilitate trading activities for shareholders. Solventum Corporation boasts a mid-range market capitalization of $12,634,768,986.00 establishing it as a steady performer. As a key player in the Medical - Care Facilities industry, the company significantly contributes to the overall market landscape, driving innovation and growth within the healthcare sector, wherein it belongs to the Healthcare sector. This combination of solid financial performance and strategic positioning underscores Solventum Corporation’s potential as a valuable investment opportunity within the dynamic healthcare market.
Is Solventum Corporation (SOLV) a good investment?
Investing in Solventum Corporation (SOLV) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
What is Solventum Corporation (SOLV)'s stock forecast?
Analysts predict Solventum Corporation stock to fluctuate between $60.70 (low) and $85.92 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Solventum Corporation's market capitalization?
As of 2025-10-20, Solventum Corporation's market cap is $12,634,768,986, based on 173,387,800 outstanding shares.
How does Solventum Corporation compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Solventum Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Solventum Corporation (SOLV) stock?
To buy Solventum Corporation (SOLV) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SOLV. Place an order (Market, Limit, etc.).
What is the best time to invest in Solventum Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Solventum Corporation perform in the last earnings report?
Revenue: $8,254,000,000 | EPS: $2.77 | Growth: -64.44%.
Where can I find Solventum Corporation's investor relations reports?
Visit https://www.solventum.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Solventum Corporation?
You can explore historical data from here
What is the all-time high and low for Solventum Corporation stock?
All-time high: $85.92 (2025-02-26) | All-time low: $47.16 (2024-07-16).
What are the key trends affecting Solventum Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Investors with an interest in Medical Services stocks have likely encountered both Solventum (SOLV) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
zacks.com
Investors interested in stocks from the Medical Services sector have probably already heard of Solventum (SOLV) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
zacks.com
Here is how Solventum (SOLV) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
zacks.com
Solventum beats on Q2 earnings, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
seekingalpha.com
Solventum Corporation (NYSE:SOLV ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Wayde McMillan - Chief Financial Officer Garri Garrison - President of Health Information Systems Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research Thanks. Welcome, everybody.
prnewswire.com
ST. PAUL, Minn. , Sept. 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced the pricing terms of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase for an aggregate purchase price of up to $2.0 billion in cash (the "Aggregate Cap") specified series of its outstanding notes (collectively, the "Notes").
prnewswire.com
ST. PAUL, Minn. , Sept. 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced the early tender results of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase its outstanding notes of the series listed in the table below (collectively, the "Notes") for an aggregate purchase price of up to an amended $2.0 billion in cash (the "Aggregate Cap").
seekingalpha.com
Solventum Corporation (NYSE:SOLV ) 2025 Wells Fargo Healthcare Conference September 5, 2025 10:15 AM EDT Company Participants Bryan Hanson - CEO & Director Wayde McMillan - Chief Financial Officer Conference Call Participants Vikramjeet Chopra - Wells Fargo Securities, LLC, Research Division Presentation Vikramjeet Chopra Associate Equity Analyst Okay. Good morning, everyone.
prnewswire.com
ST. PAUL, Minn. , Aug. 22, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV) announced today that it has commenced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase its outstanding notes of the series listed in the table below (collectively, the "Notes") for up to $1.75 billion aggregate purchase price in cash (the "Aggregate Cap").
prnewswire.com
ST. PAUL, Minn. , Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV) (the "Company" or "Solventum") today announced the pricing of the previously announced secondary offering (the "Offering") of 8,800,000 shares of its common stock, which is expected to result in gross proceeds of approximately $648 million to 3M Company (the "Selling Shareholder").
See all news
